{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Junction+%28GEJ%29+Cancers", "query": { "condition": "Gastroesophageal Junction (GEJ) Cancers" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 97, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Junction+%28GEJ%29+Cancers&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T10:16:35.145Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07488676", "title": "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "ASP546C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2026-05-04", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-07-23T10:16:35.145Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07488676" }, { "nct_id": "NCT02443324", "title": "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Adenocarcinoma", "Adenocarcinoma of the Gastroesophageal Junction", "Non-small Cell Lung Cancer", "Carcinoma, Transitional Cell", "Biliary Tract Cancer" ], "interventions": [ { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2015-07-29", "completion_date": "2022-04-12", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-07-23T10:16:35.145Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02443324" }, { "nct_id": "NCT05107674", "title": "A Study of NX-1607 in Adults With Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer, Epithelial", "Gastric Cancer", "GastroEsophageal Junction (GEJ) Cancer", "Head and Neck Squamous Cell Carcinoma", "Metastatic or Unresectable Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)", "Malignant Pleural Mesothelioma (MPM)", "Triple Negative Breast Cancer (TNBC)", "Metastatic Urothelial Carcinoma", "Cervical Cancer", "Diffuse Large B Cell Lymphoma (DLBCL)", "Richter Transformation", "Microsatellite Stable Colorectal Carcinoma" ], "interventions": [ { "name": "NX-1607", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 345, "start_date": "2021-09-29", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-07-23T10:16:35.145Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05107674" }, { "nct_id": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Malignant Solid Tumors" ], "interventions": [ { "name": "enfortumab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2020-03-10", "completion_date": "2026-09-30", "has_results": true, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-07-23T10:16:35.145Z", "location_count": 29, "location_summary": "Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04225117" }, { "nct_id": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pharmacokinetics of Zolbetuximab", "Gastric Cancer", "Gastro-esophageal Junction (GEJ) Cancer", "Pharmacokinetics of Oxaliplatin", "Pharmacokinetics of Fluorouracil Bolus (5-FU)" ], "interventions": [ { "name": "zolbetuximab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "folinic acid", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2018-06-29", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-07-23T10:16:35.145Z", "location_count": 6, "location_summary": "Los Angeles, California • Santa Monica, California • Chicago, Illinois + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03505320" }, { "nct_id": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "INCAGN01876", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2017-04-25", "completion_date": "2021-11-09", "has_results": true, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-07-23T10:16:35.145Z", "location_count": 15, "location_summary": "Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126110" }, { "nct_id": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophagogastric Tumors", "Gastric Cancer", "Gastric Tumor", "Esophageal Cancer", "Esophageal Neoplasms", "Esophageal Tumor", "GastroEsophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Gastroesophageal Junction Tumor", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2020-08-10", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-07-23T10:16:35.145Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510285" }, { "nct_id": "NCT01498289", "title": "S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 213, "start_date": "2012-02", "completion_date": "2019-09-19", "has_results": true, "last_update_posted_date": "2019-11-07", "last_synced_at": "2026-07-23T10:16:35.145Z", "location_count": 508, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01498289" }, { "nct_id": "NCT03281369", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma" ], "interventions": [ { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "PEGylated recombinant human hyaluronidase (PEGPH20)", "type": "BIOLOGICAL" }, { "name": "BL-8040", "type": "DRUG" }, { "name": "Linagliptin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 214, "start_date": "2017-10-13", "completion_date": "2025-10-09", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-07-23T10:16:35.145Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03281369" }, { "nct_id": "NCT03504397", "title": "A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer", "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer", "Metastatic Gastric Adenocarcinoma or Cancer", "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma" ], "interventions": [ { "name": "zolbetuximab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "folinic acid", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 565, "start_date": "2018-06-21", "completion_date": "2026-09-30", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-07-23T10:16:35.145Z", "location_count": 51, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03504397" } ] }